Outlier in a BE study [Outliers]

posted by riteshsrmc  – India, 2014-01-16 13:44 (3809 d 23:49 ago) – Posting: # 12177
Views: 9,777

Hi Auditor,

By the way to which agency you are filing the product? Agreed with Dan! EMEA has clearly defined the situation in guidance. I would suggest you to look at FDA perspective as well, if you are filing to FDA. FDA does not encourage redosing to handle outliers subjects incase of non-replicate design study wherein you may carry out redosing incase of replicate design. You should be clear they way agency look at the data with or without outliers.

Complete thread:

UA Flag
Activity
 Admin contact
23,059 posts in 4,841 threads, 1,649 registered users;
47 visitors (0 registered, 47 guests [including 6 identified bots]).
Forum time: 14:34 CEST (Europe/Vienna)

There are only two kinds of scholars;
those who love ideas and those who hate them.    Emile Chartier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5